Al-Abed, Y; Bucala, R (2000) Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts. Bioconjug Chem 11:39-45
|
Al-Abed, Y; Mitsuhashi, T; Li, H et al. (1999) Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol. Proc Natl Acad Sci U S A 96:2385-90
|
Fishbane, S; Bucala, R; Pereira, B J et al. (1997) Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 52:1645-50
|
Al-Abed, Y; Bucala, R (1997) Efficient scavenging of fatty acid oxidation products by aminoguanidine. Chem Res Toxicol 10:875-9
|
Pushkarsky, T; Rourke, L; Spiegel, L A et al. (1997) Molecular characterization of a mouse genomic element mobilized by advanced glycation endproduct modified-DNA (AGE-DNA). Mol Med 3:740-9
|
Wolffenbuttel, B H; Giordano, D; Founds, H W et al. (1996) Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 347:513-5
|
Al-Abed, Y; Liebich, H; Voelter, W et al. (1996) Hydroxyalkenal formation induced by advanced glycosylation of low density lipoprotein. J Biol Chem 271:2892-6
|
Bucala, R; Vlassara, H (1995) Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26:875-88
|
Zimmerman, G A; Meistrell 3rd, M; Bloom, O et al. (1995) Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A 92:3744-8
|
Bucala, R; Mitchell, R; Arnold, K et al. (1995) Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 270:10828-32
|
Showing the most recent 10 out of 22 publications